Abstract: Levobetaxolol is a cardioselective β-blocker that has been demonstrated to reduce intraocular pressure in patients affected with primary open-angle glaucoma and ocular hypertension. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium infl ux, which might confer a neuroprotective activity. Experimental and clinical studies have demonstrated the effects of levobetaxolol on ocular hemodynamics and visual fi eld, and the pharmacologic differences between β-blockers currently used for the treatment of elevated IOP have become of more than academic interest since a number of studies have shown improvements to various extents. Unlike the initially manufactured 0.5% ophthalmic solution, levobetaxolol is suspended in a different delivery vehicle in levobetaxolol ophthalmic suspension, to increase the ocular tolerance and allow a similarity of effect with a 2-fold reduced concentration (0.25%).
Introduction
Levobetaxolol hydrochloride was introduced in the early 1980s as the fi rst cardioselective β 1 -adrenergic antagonist for the treatment of elevated intraocular pressure (IOP) (Berrospi and Leibowitz 1982) .
Levobetaxolol is a single active isomer of betaxolol, a cardioselective β 1 -adrenergic receptor-blocking agent (betaxolol is a racemic mixture of D-and the active L-isomers).
Since racemic betaxolol and other β-adrenergic antagonists have been shown to reduce IOP by a reduction of aqueous production as demonstrated by tonography and aqueous fl uorophotometry, it is assumed that levobetaxolol has a similar mechanism of action (Reiss and Brubaker 1983) . Betaxolol, by having a greater affi nity for cardiac (β 1 ) than pulmonary receptors (β 2 ), has been demonstrated to offer a reduced potential for pulmonary side effects, particularly in patients with pulmonary diseases (Weinreb et al 1988) .
Several clinical studies have demonstrated the IOP lowering effect of the drug, in patients affected with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) (Radius 1983; Caldwell et al 1984; Feghali and Kaufman 1985) .
β-blockers can act as a neuroprotectant by reducing sodium infl ux into cells, and can also protect insulted neurones by reducing infl ux of calcium. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium infl ux, which might confer a neuroprotective activity (Hoste and Sys 1998) .
Experimental and clinical studies have demonstrated the effects of levobetaxolol on ocular hemodynamics and visual fi elds, and the pharmacology differences between β-blockers currently used for the treatment of elevated IOP have become of more than academic interest since a number of studies have shown improvements to various extents (Drance 1998 (Drance , 1999 Turacli et al 1998; Harris et al 1995 Harris et al , 2000 .
Unlike the initially manufactured 0.5% ophthalmic solution, levobetaxolol is suspended in a different delivery vehicle in levobetaxolol ophthalmic suspension, to increase the ocular tolerance and allow a similarity of effect with a 2-fold reduced concentration (0.25%). The cationic exchange resin in which levobetaxolol is suspended provides microscopic beads 5 microns in diameter, and residence time in the cul-de-sac is increased with the addition of a poly-acrylic polymer (Weinreb and Jani 1992; Yarangümeli ad Kural 2004) . It has been demonstrated that levobetaxolol ophthalmic suspension has similar effi cacy in reducing the IOP in POAG and OHT patients when compared with betaxolol solution (Weinreb et al 1990) .
The present paper provides a brief review of the literature on the pharmacologic and clinical investigations on levobetaxolol.
Levobetaxolol hydrochloride ophthalmic suspension
In comparisons between non-cardioselective β-blockers in reactive airway subjects, levobetaxolol was demonstrated to have less effect on pulmonary function (FEV 1 and forced vital capacity [FVC] ) (Schoene et al 1984) , by having a greater affi nity for cardiac than pulmonary receptors.
The cardiovascular effects of levobetaxolol were compared in double-masked, crossover studies with timolol maleate ophthalmic solution 0.5%. Levobetaxolol was shown during exercise to have signifi cantly less effect on heart rate and systolic blood pressure than timolol maleate (Phan et al 1991; Yamada et al 2001) .
Betaxolol, a racemic mixture of D and the active L-isomers, is commercially available in two forms: 0.5% ophthalmic solution, and the 0.25% ophthalmic suspension.
IOP reduction
β-adrenergic receptors are present in the ciliary epitheliumprocess, choroid, retina, iris, and longitudinal and circular ciliary muscles, and at a lower percentage in the lens and cornea (Sharif et al 2001) . They are also found in the trabecular meshwork (Yarangümeli and Kural 2004) . Aqueous humor production is mediated by the non-pigmented ciliary epithelial cells of the ciliary process (Okisaka et al 1974) .
A rise in cAMP causes an increase in aqueous formation mediated by β-agonist activity (Neufeld et al 1972; Townsend and Brubaker 1980; Sears 1984) . Aqueous humor outfl ow is increased by adrenergic stimulation relaxing (cAMP stimulation) trabecular meshwork (Neufeld et al 1975; Neufeld 1978; Wiederholt 1998) .
Epinephrine and isoproterenol enhance aqueous humor outfl ow, reducing cell area and increasing intercellular space in trabecular meshwork and Schlemm's canal endothelial cells through a β-stimulation (Crider and Sharif 2002) .
In non-pigmented ciliary epithelial cells, levobetaxolol was more potent than dextrobetaxolol or racemic betaxolol at inhibiting isoproterenol-stimulated cAMP production (Nathanson 1988; Crider and Sharif 2002) .
Experimental data on the inhibition of adenylyl cyclase activity in non-pigmented ciliary epithelial cells and trabecular meshwork cells demonstrate that β 2 -receptors predominate in ciliary body and trabecular meshwork (Nathanson 1981; Coca-Prados and Wax 1986; Wax and Molinoff 1987; Friedman et al 1999; Crider and Sharif 2002) .
Levobetaxolol would therefore be expected to be more potent in decreasing aqueous humor production than dextrobetaxolol, which is supported by the fact that levobetaxolol is more potent in decreasing IOP than dextrobetaxolol. Levobetaxolol was 89-fold β 1 -selective relative to its potency at β 2 -receptors in functional assays using isolated animal tissues (guinea pig atria for β 1 -receptors, guinea pig tracheal rings for β 2 -receptors). In this study levobetaxolol demonstrated higher β 1 -and β 2 -receptor affi nities and functional potencies, and a higher β 1 -selectivity than dextrobetaxolol. Levobunolol and (l)-timolol, while having high affi nities and potencies at β 1 -and β 2 -receptors, exhibited insignifi cant β-receptor selectivity (2-and 3-fold β 1 -selective) (Sharif et al 2001) . Levobetaxolol exhibited a higher affi nity at cloned human β 1 -(ki = 0.76 nM) than at β 2 -(ki = 32.6 nM) receptors, while dextrobetaxolol was much weaker at both receptors (43-fold β 1 -selectivity for levobetaxolol) at recombinant human β 1 -and β 2 -receptors (Sharif et al 2001) .
In an animal in vivo model, levobetaxolol was more potent than dextrobetaxolol in reducing IOP by a maximum of 25.9 ± 3.2%, whereas the same dose of dextrobetaxolol reduced IOP by 15.5 ± 3.6%; the effi cacy of racemic betaxolol was very similar to that of levobetaxolol (Sharif et al 2001) .
Topical treatment with betaxolol has been shown to reduce IOP signifi cantly in normal subjects, and in POAG and OHT patients in placebo-controlled studies (Radius 1983; Caldwell et al 1984; Feghali and Kaufman 1985) , as well as in masked comparisons with timolol (Berry et al 1984; Allen et al 1986; Stewart et al 1986) , and levobunolol (Long et al 1988) . All these drugs have been found comparable with regard to their effi cacy in lowering IOP; however, the Levobetaxolol hydrochloride decrease of IOP has been found to be signifi cantly smaller with betaxolol compared with timolol or levobunolol in a number of clinical trials (Radius 1983; Caldwell et al 1984; Berry et al 1984; Feghali and Kaufman 1985; Stewart et al 1986; Allen et al 1986; Long et al 1988; Messmer et al 1991; Kaiser et al 1994; Yarangümeli and Kural 2004) .
In two controlled clinical studies, in which a total of 356 patients were dosed for 3 months, betaxolol ophthalmic suspension produced clinically relevant reductions in IOP at all follow-up visits. At 8 AM after night-time dosing (trough), IOP was reduced from baseline by approximately 4-5 mmHg (16%-21%). At 10 AM, 2 hours after dosing (peak), IOP was reduced from baseline by approximately 5-6 mmHg (20% to 23%) (Weinreb et al 1990) .
Adverse effects
Although betaxolol is pharmacodynamically selective for β 1 -adrenoreceptors, the extent of β 1 -receptor occupancy of topically applied betaxolol in the systemic circulation has been found to be less than that of the three non-selective blockers: timolol, levobunolol, and carteolol (Phan et al 1991; Yamada et al 2001) ; this indicates a lesser systemic β 1 -blocking activity of betaxolol, associated with negligible systemic β 2 -blockade, which provides a better safety profi le for the drug.
Systemic absorption allows topical β-adrenergic blockers to cause adverse effects on pulmonary, cardiac and central nervous system (Van Buskirk 1980; Le Jeunne et al 1990) . Non-selective β-blockers commonly used in glaucoma therapy cause bronchopulmonary constriction and depress cardiovascular performance (Le Jeunne et al 1990; Sharif et al 2001) while selective β-blockers such as betaxolol and levobetaxolol do not have this side effect. In the heart β 1 -adrenoceptors predominate, while in the lung and trachea there is a predominance of β 2 -adrenoceptors (Rugg et al 1978; Henry et al 1990; Satoh et al 1993) . Sharif and Xu (2004) determined the relative affi nities and selectivities of timolol, levobunolol, levobetaxolol racemic betaxolol, and other β-blockers at the native β 1 -and β 2 -adrenoceptors in guinea pig heart and lung using radioligand binding, demonstrating that racemic betaxolol and levobetaxolol exhibited a higher affi nity and greater selectivity for the β-adrenoceptors than the destro enantiomer.
Betaxolol and levobetaxolol possessed a 193-to 233-fold selectivity for β 1 -receptors, and levobunolol a 140-fold selectivity for β 2 -receptors; timolol was essentially non-selective.
Any ocular hypotensive treatment that can reduce blood pressure and heart rate can act as an additional risk factor in the development and progression of POAG (Quaranta et al 2006) . Most of the studies have shown the lack of effects of betaxolol on the cardiovascular system (Berrospi and Leibowitz 1982; Caldwell et al 1984; Feghali and Kaufman 1985; Berry et al 1984; Long et al 1988) .
Due to the very low binding affinity to pulmonary β 2 -receptors, betaxolol is generally well tolerated and does not produce signifi cant modifi cation of pulmonary function tests in glaucoma patients with asthma and chronic obstructive pulmonary disease (Weinreb et al 1988; Van Buskirk et al 1986; Goldberg and Goldberg 1995; Schoene et al 1984) .
However, it should be remembered that some pulmonary complications have also been reported associated with betaxolol treatment (Harris et al 1986; Roholt 1987) .
Effects on ocular blood fl ow
Betaxolol can improve ocular perfusion, increasing blood velocity in retinal and epipapillary capillaries (Arend et al 1998) ; can increase end-diastolic velocity and decrease resistance index trough (determined by color Doppler imaging), a vasorelaxant effect in retrobulbar vessels (posterior ciliary arteries, central retinal artery) (Harris et al 1995; Steigerwalt et al 2001) ; and can increase retinal blood fl ow as a long-term effect after drug application (Yoshida et al 1998) . Kulkarni and De Santis (2001) demonstrated the vasorelaxant effects of DL-betaxolol, D-betaxolol, and L-betaxolol on bovine retinal vessels. The compounds had the same vasodilatatory effect without statistically signifi cant differences.
Levobetaxolol would have the same action on blood ocular vessels as racemic betaxolol (unrelated to stereoselective β-blocking activity), perhaps involving an interaction with calcium channels.
Calcium-sodium channel blocking activity and neuroprotection β 1 -blockers can act as neuroprotectants by reducing sodium infl ux into cells acting as; they can also protect insulted neurones by reducing calcium infl ux. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium infl ux (Melena et al 1999; Chidlow et al 2000; Osborne et al 2004) .
An ischemic-like insult to the optic nerve causes a decline of ATP and failure of the NA + /K + -ATPase, which leads to an accumulation of intra-axonal sodium. This rise in intracellular sodium leads to reversal of the NA + /Ca 2+ exchanger, which imports damaging quantities of calcium into the intracellular compartment. Elevated extracellular concentrations of glutamate cause excitotoxic injury, leading to an excessive stimulation of ganglion cell glutamate receptors and an entry of Ca + and Na + ions. This rise in ion concentration will activate the opening of voltage-gated channels and cause a greater elevation of Na + and Ca + concentration, a trigger for a cascade of events that lead to cell death.
Glutamate receptor antagonist or the use of sodium or calcium channel blockers can protect the ganglion cell bodies from excitotoxic injury. Glutamate antagonists would not be effective at the axonal level, so to protect the entire ganglion cell in glaucoma, the ideal way would be that of using a glutamate receptor antagonist together with a sodium-channel blocker or a substance that prevents the reversal of sodium/calcium exchanger (Osborne et al 2004) .
Betaxolol can inhibit Na + infl ux modulating the gating mechanism of the Na + channel, not interfering with ion conductance directly. Betaxolol inhibited veratridine-stimulated (lipophilic toxin that causes a persistent activation of the Na + channel) Na + infl ux into rat cortical synaptosomes without statistically signifi cant differences between the effects of levobetaxolol and that of racemic betaxolol, so that it is possible to conclude that stereoselectivity is not relevant to the affi nity of betaxolol for the neurotoxin site 2 of the Na + channel. Atenolol, timolol, levobunolol, and cateolol were signifi cantly less active than betaxolol (Chidlow et al 2000) .
It has been demonstrated that betaxolol has an affi nity for the L-type voltage-gated calcium channel and is able to counteract the N-methyl-D-aspartate-induced infl ux of radioactive calcium into the retina (Melena et al 2001) . Osborne et al (2004) , using an ischemia/reperfusion model recording fl ash electroretinograms after a reperfusion period in ischemic rat retinas, showed that levobetaxolol is more effective than timolol as a neuroprotectant.
Levobetaxolol demonstrates a higher affi nity than dextrobetaxolol against L-type Ca + channels, but no signifi cant affi nity at N-type Ca + channels. Levobetaxolol is able to counteract the NMDA-induced infl ux of radioactive calcium into rat retinas (Sharif et al 2001; Melena et al 2001) . This L-type Ca + channel blocking activity is clinically relevant because an increase in optic nerve head blood fl ow and benefi cial effects on visual fi elds in glaucoma patients are associated with various Ca 2+ -antagonists (Cellini et al 1997; Koseki et al 1999) .
Levobetaxolol could act as a neuroprotectant both for the axon (in which voltage-sensitive sodium channels are responsible for generation and propagation of action potentials) (Chidlow et al 2000) , and for the cell body and dendrites, reducing the toxic infl ux of calcium glutamate-mediated (Osborne et al 2004) blocking of both calcium and sodium channels.
Furthermore, it has been shown that systemic dosed levobetaxolol exerts a neuroprotective action in photic-induced retinal damage. This molecule can upregulate endogenous b-fi broblast growth factor and ciliary neurotrophic factormRNA (two growth factors implicated in the protection of photoreceptor cells). Levobetaxolol was able to protect the retinal function (tested with an electroretinogram), and to prevent changes in retinal morphology after photic-induced retinopathy (Agarwal et al 2002) .
Conclusions
Betaxolol is a well-documented drug in glaucoma therapy, and its effi cacy in lowering the IOP is comparable with that of the non-selective β-blockers.
Betaxolol offers a superior safety profi le, especially in patients with cardio-pulmonary diseases. Due to the calcium channel-blocker activity, betaxolol has all the characteristics for improving ocular perfusion and protecting retinal ganglion cells from loss related to glaucoma.
